Metrics as of 10/13/2026, 06:51 PM (Berlin time), refresh in progress.
SAB Biotherapeutics Stock
SAB Biotherapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Samuel J. Reich
- Employees
- 86
- Market cap
- $244 M
- IPO
- 09/02/2021
- Web
- www.sab.bio
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable…
SAB Biotherapeutics stock: price history
1D
-5.3%
1W
-8.5%
1M
-21.4%
6M
-30.6%
YTD
-28.3%
1Y
+16.0%
2Y
+11.7%
5Y
-97.3%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~51% stronger price swings than usual
Ask the agents about SAB Biotherapeutics
Analyst assessment of SAB Biotherapeutics
PRICE TARGET LOW
US$10.00
CONSENSUS
US$11.33
MEDIAN
US$11.00
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 17/06/2026
SAB Biotherapeutics stock metrics
P/E
0.75
P/B
1
EV/EBITDA
-25.53
RETURN ON EQUITY
-10.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.2%
FLOAT SHARES
76,625,015
AVG. DAILY VOLUME (30D)
612,483
Insider transactions (SEC)
Kropotova Alexandra
Kropotova Alexandra
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about SAB Biotherapeutics stock
What does SAB Biotherapeutics do?
SAB Biotherapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Samuel J. Reich, the company employs around 86 people.
The IPO was on 09/02/2021; the stock trades on NASDAQ under the ticker SABS.
What do analysts say about SAB Biotherapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 17/06/2026).
The average price target is US$11.33, ranging from US$10.00 to US$13.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does SAB Biotherapeutics report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 51% stronger than usual.
Does SAB Biotherapeutics pay a dividend?
No, SAB Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to SAB Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get SAB Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess SAB Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.